• About us
• Contact

Advertisement

Organisation › Details

Agennix AG

Agennix AG is a publicly listed biopharmaceutical company that is focused on the development of novel therapies that have the potential to substantially improve the length and quality of life of critically ill patients in areas of major unmet medical need. The Company's most advanced program is talactoferrin, a first-in-class oral Dendritic Cell Mediated Immunotherapy (DCMI). Talactoferrin is currently in Phase III clinical trials in non-small cell lung cancer. Other clinical development programs include RGB-286638, a multi-targeted kinase inhibitor in Phase I testing for cancer, and a topical gel form of talactoferrin for diabetic foot ulcers. Agennix's registered seat is in Heidelberg, Germany. The Company has three sites of operation: Planegg/Munich, Germany; Princeton, New Jersey and Houston, Texas. *

 

	Start	1993-01-01 established
	End	2013-05-31 dissolved
	Group	HOPP Group (family of Dietmar Hopp)
	Predecessor	GPC Biotech AG
	Industry	talactoferrin
	Region	Heidelberg
	Country	Germany
	Street	515 Im Neuenheimer Feld
	City	69120 Heidelberg
		Address record changed: 2020-12-02
Basic data	Employees	B: 11 to 50 (2012-11-01)
		* Document for »About Section«:
		Record changed: 2023-12-30

Advertisement

More documents for HOPP Group (family of Dietmar Hopp)

• [1] AaviGen GmbH. (7/26/23). "Press Release: AaviGen Raises 17 Million € in Second Financing Round to Advance Precision Gene Therapies for Heart Failure towards the Clinical Stage". Heidelberg....
• [2] Heidelberg Pharma AG. (2/17/22). "Press Release: Heidelberg Pharma AG Secures Financing Commitment From its Main Shareholder dievini (ad hoc)". Ladenburg....
• [3] CureVac B.V.. (8/18/20). "Press Release: CureVac Announces Closing of Initial Public Offering". Tübingen & Boston, MA....
• [4] Heidelberg Pharma AG. (4/27/20). "Press Release: Heidelberg Pharma AG Raises EUR 14.4 Million from Private Placement". Ladenburg....
• [5] dievini Hopp BioTech holding GmbH & Co. KG. (3/15/20). "Press Release: dievini nimmt Stellung zu Presseveröffentlichungen über ihre Beteiligungsgesellschaft". Walldorf....
• [6] Heidelberg Pharma AG. (1/22/20). "Press Release: Heidelberg Pharma AG Secures Financing Commitment from Its Main Shareholder Dievini". Ladenburg....
• [7] CRS Clinical Research Services Andernach GmbH. (4/19/19). "Press Release: Management Buy-Out at CRS. Apleonex AG Buys LTS AG’s Shares in CRS Clinical Research Services Andernach GmbH". Andernach....
• [8] Hofmann, Siegfried / Brors, Peter. (12/5/18). "News: Interview – Dietmar Hopp glaubt an seine Biotechs – »Wir werden unseren Einsatz verdreifachen«"....
• [9] CureVac AG. (5/8/18). "Press Release: CureVac Announces New Management Structure. Founder Ingmar Hoerr to Transition to Chairman role; Daniel Menichella to Become CEO". Tübingen....
• [10] BRAIN AG. (12/15/17). "Press Release: BRAIN Achieves Clear Improvement in Revenues and Earnings in the 2016/17 Financial Year". Zwingenberg....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.